Membranoproliferative glomerulonephritis and C3 glomerulopathy

Daniel P. Gale and Terry Cook

in Oxford Textbook of Clinical Nephrology

Fourth edition

Published on behalf of Oxford University Press

Published in print October 2015 | ISBN: 9780199592548
Published online October 2015 | e-ISBN: 9780191779145 | DOI:

Series: Oxford Textbook

Membranoproliferative glomerulonephritis and C3 glomerulopathy

Show Summary Details


Membranoproliferative glomerulonephritis (MPGN) is synonymous with mesangiocapillary glomerulonephritis and refers to light microscopic appearances of a kidney biopsy in which there are increased mesangial cells and matrix with thickening of the glomerular capillary walls, often with a double contour appearance. MPGN represents morphological appearances caused by a wide range of diseases, most of which are systemic and involve activation of the immune system. It commonly presents as nephrotic syndrome, alternatively with proteinuria, haematuria, and varying degrees of hypertension and renal dysfunction. MPGN was historically characterized into types 1–3 according to the location of immune deposits, but a more useful classification is by whether the underlying disorder results in prominent glomerular immunoglobulin deposition (with secondary complement deposited) or if there is glomerular complement, but scanty or no immunoglobulin deposited. The immunoglobulin group includes MPGN caused by infections, autoimmunity, cryoglobulinaemia, and paraprotein production. The complement group (C3 glomerulopathy) includes dense deposit disease and other complement disorders. Similar light microscopic appearances without deposition of immunoglobulin or complement are sometimes seen in patients with chronic thrombotic microangiopathies. Management and prognosis depend on aetiology.

Chapter.  5657 words.  Illustrated.

Subjects: Nephrology ; Surgery

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.